Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Introducing ‘The Hive’

Posted on May 4th, 2016 by

Pharma R&D

Elsevier Hive

Fifty-four percent. That’s the percentage of “all active drugs” sourced via open innovation models for the 12 largest biopharma company pipelines in 2014. Continue reading “Introducing ‘The Hive’” »

Drug Repurposing for Rare Diseases

Posted on April 27th, 2016 by

Pharma R&D

Dr Nicolas Sireau, Findacure

Elsevier’s partnership with a UK charity Findacure started last year with a very touching and inspirational talk from Dr. Nick Sireau, a parent of two children diagnosed with alkaptonuria. Very soon after his first child was born, Nick found himself Continue reading “Drug Repurposing for Rare Diseases” »

Biosimilars and Pharmacovigilance: What You Need to Know—and Do—Now

Posted on April 26th, 2016 by

Pharmacovigilance

injection

A few weeks ago, the US FDA approved Inflectra (infliximab-dyyb), a biosimilar to infliximab. This is the second US biosimilar approval, suggesting others may soon be on the way—good news for companies with biosimilars pending approval and in development. Continue reading “Biosimilars and Pharmacovigilance: What You Need to Know—and Do—Now” »

The Essentials of Pharmacovigilance

Posted on April 19th, 2016 by

Pharmacovigilance

PVblog

Elsevier is attending the World Drug Safety Congress in Chicago this week—an important part of the pharmaceutical industry calendar that brings together experts Continue reading “The Essentials of Pharmacovigilance” »

Green and Sustainable Chemistry Conference

Posted on April 15th, 2016 by

Chemistry

R_D_Solutions_Blog_Image_green_sustainable_chemistry_conference_DIGITAL

It felt like an impromptu 25th birthday party for green chemistry. What a feast of speakers there were at the Green and Sustainable Chemistry conference in Berlin last week! Continue reading “Green and Sustainable Chemistry Conference” »

Trail-blazing innovation – Seeking the new blockbuster

Posted on April 11th, 2016 by

Pharma R&D

blockbuster drugs

The Holy Grail of the 21st century, at least for pharmaceutical companies, is the one blockbuster drug that will reap rewards of $1Billion+ in peak sales. Continue reading “Trail-blazing innovation – Seeking the new blockbuster” »

  1. 1
  2. 44
  3. 45
  4. 46
  5. 47
  6. 48
  7. 55


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.